je.st
news
Tag: asco
EMD Serono to Release New Pipeline Data at ASCO 2014 from Early-Stage ...
2014-05-29 09:59:38| Logistics - Topix.net
ASCO abstract #: Anti-PD-L1: 3064; c-Met: 2521, TPS4151, TPS8121; tecemotide: TPS3658, TPS7608; TH-302: 8534, 2029; further pipeline: 3551, TPS9107, 5030, 2050, e13552 Data from nine EMD Serono pipeline products across oncology and immuno-oncology to be presented, including anti-PD-L1, c-Met inhibitor and TH-302 , today announced that new data from ... (more)
Tags: data
release
pipeline
asco
ImmunoGen, Inc. Announces Clinical Data Presentations at Upcoming 50th Annual Meeting of ASCO
2014-05-15 18:18:39| Logistics - Topix.net
New clinical data are being presented on ImmunoGen wholly owned compounds, IMGN529 and IMGN853, as well as on partner compounds SAR3419, SAR650984 and Kadcyla .
Eisai to Present New Research on Oncology Products and Pipeline at 50th Asco Annual Meeting
2014-05-15 07:54:39| Logistics - Topix.net
Highlights Include New Phase Iii Clinical Data on Investigational Anticancer Agent Lenvatinib in Radioiodine-Refractory Differentiated Thyroid Cancer Tokyo, May 15, 2014 - - Eisai Co., Ltd. announced today that a series of abstracts highlighting new study results on Halaven and lenvatinib with a novel binding mode) will be presented during the 50th ... (more)
Tags: products
research
present
meeting
Mercks Investigational Anti-PD1 Antibody, MK-3475, Active in Three Different Tumor Types: New Data to be Presented at the 2014 ASCO Annual Meeting
2014-05-14 14:00:00| Merck.com - Corporate News
Dateline City: WHITEHOUSE STATION, N.J. Six oral presentations report MK-3475 monotherapy data across three different tumor types and multiple lines of therapy Late-breaker presentation of long-term findings of MK-3475 in advanced melanoma, including ipilimumab-nave and treated settings; data included in ASCO Press Program First presentation of findings evaluating MK-3475 as initial treatment of patients with advanced non-small cell lung cancer First presentation of findings of MK-3475 in recurrent/metastatic head and neck cancer WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that new data for the companys investigational anti-PD-1 antibody, MK-3475, in advanced melanoma, non-small cell lung cancer (NSCLC), and head and neck cancer, are scheduled to be presented at the 50th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago on May 30 June 3, 2014. Language: English Contact: MerckMedia:Ian McConnell, 908-423-3046orClaire Mulhearn, 908-423-7425orInvestors:Carol Ferguson, 908-423-4465orJustin Holko, 908-423-5088 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Ignyta: RXDX-101 Phase I Data Abstract Chosen for Oral Presentation at ASCO
2014-05-12 10:06:25| Logistics - Topix.net
Presenter: , M.D., Fondazione IRCCS Istituto Nazionale dei Tumori Session: Developmental Therapeutics - Clinical Pharmacology and Experimental Therapeutics.
Tags: data
abstract
phase
presentation
Sites : [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] next »